9/28/2010

Children’s Technology Development Fund Awards $1.3 Million to Further Innovation


TDF Brick

Children’s Hospital Boston’s Technology Development Fund announces second annual award winners to support clinical and research innovations to improve and save lives.

Children’s Hospital Boston’s Technology and Innovation Development Office (TIDO) named the recipients for this year’s Technology Development Fund (TDF), which supports the advancement of promising clinical and research innovations. More than $1.3 million will be used to cultivate 11 technologies that range from pharmaceuticals, diagnostics and medical devices to drug delivery and software.

The projects seek to advance innovation in various medical fields and produce new technologies, including: a prolonged-duration anesthetic; a novel therapeutic for metastatic cancer; software for assessment of early autism; and a medical device for the diagnosis of dehydration.

“As funding to advance early-stage discoveries and innovations continues to lag, the Technology Development Fund seeks to fill that gap for our most promising technologies,” says Erik Halvorsen, PhD, director of TIDO. “This mechanism, which brings capital and industry experts to bear on Children’s innovations, is critical for translating our research into new diagnostics, devices and therapeutics that can benefit our young patients.”

“The Technology Development Fund has allowed us the freedom to innovate and form collaborations that are essential to further the development of early stage technology,” said John Kheir, MD, department of cardiology and award recipient. “Without the unique resources and expertise from this fund, we might never see our concepts come to fruition.”

Below is the list of funded projects and investigators:

  • Site 1 sodium channel blocker as a prolonged duration local anesthetic (Charles Berde, MD, PhD, Anesthesiology) [more here]
  • Optical device to monitor capillary refill (Vassilios Bezzerides, MD, PhD, Cardiology) [more here]
  • Early autism diagnosis and risk assessment using complex systems analysis of EEG signals (William Bosl, PhD, Medicine/Informatics Program) [more here]
  • A GDNF receptor agonist for topical treatment of peripheral neuropathies (Gabriel Corfas, PhD, Neurology and Otolaryngology) [more here]
  • Novel transillumination (PICC) line catheter (Farhad Imam, MD, Newborn Medicine/Surgery) [more here]
  • I.V. oxygen using injectable microbubbles (John Kheir, MD, Anesthesiology) [more here]
  • Platform to deliver vaccines and drugs across the intestinal wall (Wayne Lencer, MD, Medicine) [more here]
  • Novel myocardial PET imaging agent (Alan Packard, PhD, and S. Ted Treves, MD, Division of Nuclear Medicine and Molecular Imaging) [more here]
  • Development of Saposin A derivatives as a cancer therapeutic (Randolph Watnick, PhD, Vascular Biology Program) [more here]
  • Ion channel blockers to manage neurogenic inflammation (Clifford Woolf, PhD, BCh, MD, Neurobiology Program) [more here]
  • Novel therapeutic approach for metastatic prostate cancer (Bruce Zetter, PhD, Surgery) [more here]

Investigators will be paired with members of the TDF advisory board who will work with Halvorsen and Monique Yoakim-Turk, PhD, technology development manager of TIDO, to guide each project. Additionally, TIDO selects, negotiates and executes the appropriate agreements with Contract Research Organizations (CROs) before the initiation of each project.

The TDF has significantly advanced stages of development in more than ten Children’s innovations from last year’s first-time award winners. All have resulted in new commercial partnerships, follow-on funding and generated data that is being prepared for publication.

For more information about the TDF, visit our website at: http://childrensinnovations.org/Pages/HospitalCommunity/TechnologyDevelopmentFund.aspx

Children's HospitalTerms and Conditions
Site Designed and Developed by Genuine